 WATERTOWN, Mass., June 21, 2021 GLOBE NEWSWIRE -- C4 Therapeutics, Inc. C4T Nasdaq: CCC, a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced the closing of an underwritten public offering of 4,887,500 shares of its common stock, including the exercise in full by the underwriters of their option to purchase up to an additional 637,500 shares of common stock, at a public offering price of 37.00 per share. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately 180.8 million. All of the shares in the offering were offered by C4T. 